Knowledge Tree
non-small cell lung cancer
Also known as: NSCLC
Facts (6)
Sources
Cellular rejuvenation: molecular mechanisms and potential ... - Nature nature.com Mar 14, 2023 4 facts
claimCisplatin-based chemotherapy in non-small cell lung cancer inactivates p53 and induces Tribbles Pseudokinase 1 expression, leading to stemness activation in cancer cells.
claimThe combination of cisplatin and a histone deacetylase inhibitor may synergistically suppress the progression of non-small cell lung cancer.
claimLkb1 deficiency induces the trans-differentiation of adenocarcinoma cells into squamous cell carcinoma in non-small cell lung cancer.
claimCisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer by enhancing TRIB1 and HDAC activity, as reported by et al. in Cell Death & Disease (2017).
Cellular senescence: from homeostasis to pathological implications ... frontiersin.org 1 fact
claimEGFR oncogenic mutations in non-small cell lung cancer (NSCLC) impair macrophage phagocytosis and mediate innate immune evasion by up-regulating CD47.
How does targeted therapy treat cancer? | UT MD Anderson mdanderson.org Jun 7, 2024 1 fact
claimThe drug selpercatinib is approved to treat any cancer driven by a RET fusion, including medullary and papillary thyroid cancers, non-small cell lung cancer, colorectal cancer, and bile duct cancer.